Academic Content and Language Evaluation of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (10429)
All Articles published online
|
Featured Article
|
Publishing Process of This Article
|
May 14, 2015 (publication date) through Nov 24, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Qi XS, Guo XZ, Han GH, Li HY, Chen J. MET inhibitors for treatment of advanced hepatocellular carcinoma: A review. World J Gastroenterol 2015; 21(18): 5445-5453 [PMID: 25987766 DOI: 10.3748/wjg.v21.i18.5445] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v21/i18/5445.htm |
| Number | Citing Articles |
| 1 |
Natália Bertoni, Lied M. S. Pereira, Fábio E. Severino, Regina Moura, Winston B. Yoshida, Patricia P. Reis. Integrative meta-analysis identifies microRNA-regulated networks in infantile hemangioma. BMC Medical Genetics 2016; 17(1) doi: 10.1186/s12881-015-0262-2
|
| 2 |
Hyungjin Rhee, Hye-Young Kim, Ji-Hye Choi, Hyun Goo Woo, Jeong Eun Yoo, Ji Hae Nahm, Jin-Sub Choi, Young Nyun Park. Keratin 19 Expression in Hepatocellular Carcinoma Is Regulated by Fibroblast-Derived HGF via a MET-ERK1/2-AP1 and SP1 Axis. Cancer Research 2018; 78(7): 1619 doi: 10.1158/0008-5472.CAN-17-0988
|
| 3 |
Derion Reid, Carla Mattos. Unravelling Cancer Signaling Pathways: A Multidisciplinary Approach. 2019; : 295 doi: 10.1007/978-981-32-9816-3_12
|
| 4 |
Wenjian Min, Yanyin Wang, Hongtao Shen, Mingming Zheng, Chen Tong, Hao Shen, Dawei Wang, Yasheng Zhu, Xiao Wang, Yibei Xiao, Xiao-Yu Zhang, Peng Yang. Discovery of potent and selective c-Met inhibitors for MET-amplified hepatocellular carcinoma treatment. European Journal of Medicinal Chemistry 2024; 264: 116025 doi: 10.1016/j.ejmech.2023.116025
|
| 5 |
Takahiro Kodama, Justin Y. Newberg, Michiko Kodama, Roberto Rangel, Kosuke Yoshihara, Jean C. Tien, Pamela H. Parsons, Hao Wu, Milton J. Finegold, Neal G. Copeland, Nancy A. Jenkins. Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma. Proceedings of the National Academy of Sciences 2016; 113(24) doi: 10.1073/pnas.1606876113
|
| 6 |
Jiaojiao Guo, Qi Tang. Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma. Cancer Gene Therapy 2021; 28(10-11): 1075 doi: 10.1038/s41417-020-00259-4
|
| 7 |
Sung Min Kim, Jang Mi Han, Tuoi Thi Le, Jae Kyung Sohng, Hye Jin Jung. Anticancer and Antiangiogenic Activities of Novel α-Mangostin Glycosides in Human Hepatocellular Carcinoma Cells via Downregulation of c-Met and HIF-1α. International Journal of Molecular Sciences 2020; 21(11): 4043 doi: 10.3390/ijms21114043
|
| 8 |
Mengqi Xin. Research and Treatment Progress of Capmatinib in Hepatocellular Carcinoma. Highlights in Science, Engineering and Technology 2022; 8: 576 doi: 10.54097/hset.v8i.1217
|
| 9 |
Han Xiao, Ben Wang, Hai‐Xia Xiong, Jia‐Fu Guan, Jian Wang, Tao Tan, Kang Lin, Shu‐Bing Zou, Zhi‐Gang Hu, Kai Wang. A novel prognostic index of hepatocellular carcinoma based on immunogenomic landscape analysis. Journal of Cellular Physiology 2021; 236(4): 2572 doi: 10.1002/jcp.30015
|
| 10 |
Bryan Fleming, Mitchell Ho. Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer. Toxins 2016; 8(10): 274 doi: 10.3390/toxins8100274
|
| 11 |
Rui Cao, Hongguang Liu , Zhen Cheng. Radiolabeled Peptide Probes for Liver Cancer Imaging. Current Medicinal Chemistry 2020; 27(41): 6968 doi: 10.2174/0929867327666200320153837
|
| 12 |
Xiaohan Cui, Xiao Yun, Meiling Sun, Renzhi Li, Xiajie Lyu, Yuanxiang Lao, Xihu Qin, Wenbin Yu. HMGCL-induced β-hydroxybutyrate production attenuates hepatocellular carcinoma via DPP4-mediated ferroptosis susceptibility. Hepatology International 2023; 17(2): 377 doi: 10.1007/s12072-022-10459-9
|
| 13 |
Smriti Verma, Bidya Dhar Sahu, Madhav Nilakanth Mugale. Role of lncRNAs in hepatocellular carcinoma. Life Sciences 2023; 325: 121751 doi: 10.1016/j.lfs.2023.121751
|
| 14 |
Tianpeng Jiang, Zhi Huang, Shuai Zhang, Weijie Zou, Lei Xiang, Xiaowen Wu, Yaping Shen, Weixin Liu, Zhu Zeng, Ansu Zhao, Shi Zhou, Qingfan Zeng. miR‑23b inhibits proliferation of SMMC‑7721 cells by directly targeting IL‑11. Molecular Medicine Reports 2018; doi: 10.3892/mmr.2018.9151
|
| 15 |
Yongqing Qin, Shisong Han, Yahan Yu, Ding Qi, Mengnan Ran, Mingqi Yang, Yanyan Liu, Yunyi Li, Ligong Lu, Yu Liu, Yong Li. Lenvatinib in hepatocellular carcinoma: Resistance mechanisms and strategies for improved efficacy. Liver International 2024; 44(8): 1808 doi: 10.1111/liv.15953
|
| 16 |
Yongxi Tong, Mingshan Wang, Haijun Huang, Jiajie Zhang, Yicheng Huang, Yingjun Chen, Hongying Pan. Inhibitory effects of genistein in combination with gefitinib on the hepatocellular carcinoma Hep3B cell line. Experimental and Therapeutic Medicine 2019; doi: 10.3892/etm.2019.8027
|
| 17 |
Dan-Dan Wang, Ying Chen, Zi-Bo Chen, Fang-Jie Yan, Xiao-Yang Dai, Mei-Dan Ying, Ji Cao, Jian Ma, Pei-Hua Luo, Yong-Xin Han, Yong Peng, Ying-Hui Sun, Hui Zhang, Qiao-Jun He, Bo Yang, Hong Zhu. CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation. Molecular Cancer Therapeutics 2016; 15(12): 2916 doi: 10.1158/1535-7163.MCT-16-0282
|
| 18 |
Shankun Zhao, Weizhou Wu, Hao Jiang, Lei Ma, Chengyi Pan, Chong Jin, Jinggang Mo, Liezhi Wang, Kunpeng Wang. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib?. Frontiers in Immunology 2021; 12 doi: 10.3389/fimmu.2021.731527
|
| 19 |
Xiao‐Han Cui, Qiu‐Ju Peng, Ren‐Zhi Li, Xia‐Jie Lyu, Chun‐Fu Zhu, Xi‐Hu Qin. Cell division cycle associated 8: A novel diagnostic and prognostic biomarker for hepatocellular carcinoma. Journal of Cellular and Molecular Medicine 2021; 25(24): 11097 doi: 10.1111/jcmm.17032
|
| 20 |
Jianqun Kou, Phillip R. Musich, Ben Staal, Liang Kang, Yuan Qin, Zhi Q. Yao, Boheng Zhang, Weizhong Wu, Angela Tam, Alan Huang, Huai-Xiang Hao, George F. Vande Woude, Qian Xie. Differential responses of MET activations to MET kinase inhibitor and neutralizing antibody. Journal of Translational Medicine 2018; 16(1) doi: 10.1186/s12967-018-1628-y
|
| 21 |
Hideo Tomihara, Daisaku Yamada, Hidetoshi Eguchi, Yoshifumi Iwagami, Takehiro Noda, Tadafumi Asaoka, Hiroshi Wada, Koichi Kawamoto, Kunihito Gotoh, Yutaka Takeda, Masahiro Tanemura, Masaki Mori, Yuichiro Doki. MicroRNA‐181b‐5p, ETS1, and the c‐Met pathway exacerbate the prognosis of pancreatic ductal adenocarcinoma after radiation therapy. Cancer Science 2017; 108(3): 398 doi: 10.1111/cas.13159
|
| 22 |
Yubin Wang, Hao Xu, Juan Yang, Juyi Zhang. The effectiveness of tivantinib for MET-high hepatocellular carcinoma: A protocol for meta analysis. Medicine 2023; 102(16): e32591 doi: 10.1097/MD.0000000000032591
|
| 23 |
Guang-li Luo, Bian-qin Guo, Li-xiang Wu, Yan-xi Shen, Tingting Xie, Xi Wei. Application of Tivantinib for Hepatocellular Carcinoma: A Meta-Analysis Study. Evidence-Based Complementary and Alternative Medicine 2022; 2022: 1 doi: 10.1155/2022/1976788
|
| 24 |
Yuichi Kumaki, Goshi Oda, Sadakatsu Ikeda. Targeting MET Amplification: Opportunities and Obstacles in Therapeutic Approaches. Cancers 2023; 15(18): 4552 doi: 10.3390/cancers15184552
|
| 25 |
Daniel Neureiter, Sebastian Stintzing, Tobias Kiesslich, Matthias Ocker. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets. World Journal of Gastroenterology 2019; 25(25): 3136-3150 doi: 10.3748/wjg.v25.i25.3136
|
| 26 |
Shukui Qin, Stephen Lam Chan, Wattana Sukeepaisarnjaroen, Guohong Han, Su Pin Choo, Virote Sriuranpong, Hongming Pan, Thomas Yau, Yabing Guo, Minshan Chen, Zhenggang Ren, Jianming Xu, Chia-Jui Yen, Zhong-Zhe Lin, Luigi Manenti, Yi Gu, Yongjian Sun, Ralph Tiedt, Lu Hao, Wenjie Song, Tawesak Tanwandee. A phase II study of the efficacy and safety of the MET inhibitor capmatinib (INC280) in patients with advanced hepatocellular carcinoma. Therapeutic Advances in Medical Oncology 2019; 11 doi: 10.1177/1758835919889001
|
| 27 |
Xiangming Xu, Lei Yao. Recent Patents on the Development of c-Met Kinase Inhibitors. Recent Patents on Anti-Cancer Drug Discovery 2020; 15(3): 228 doi: 10.2174/1574892815666200630102344
|
| 28 |
J. Sastre, R. Díaz-Beveridge, J. García-Foncillas, R. Guardeño, C. López, R. Pazo, N. Rodriguez-Salas, M. Salgado, A. Salud, J. Feliu. Clinical guideline SEOM: hepatocellular carcinoma. Clinical and Translational Oncology 2015; 17(12): 988 doi: 10.1007/s12094-015-1451-3
|
| 29 |
Jordan N. Markowitz, Karen M. Fancher. Cabozantinib: A Multitargeted Oral Tyrosine Kinase Inhibitor. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 2018; 38(3): 357 doi: 10.1002/phar.2076
|
| 30 |
Supritha G. Swamy, Vivek H. Kameshwar, Priya B. Shubha, Chung Yeng Looi, Muthu K. Shanmugam, Frank Arfuso, Arunasalam Dharmarajan, Gautam Sethi, Nanjunda Swamy Shivananju, Anupam Bishayee. Targeting multiple oncogenic pathways for the treatment of hepatocellular carcinoma. Targeted Oncology 2017; 12(1): 1 doi: 10.1007/s11523-016-0452-7
|
| 31 |
|
| 32 |
Hao Zhang, Zhengqiang Bao, Hongwei Liao, Wen Li, Zhihua Chen, Huahao Shen, Songmin Ying. The efficacy and safety of tivantinib in the treatment of solid tumors: a systematic review and meta-analysis. Oncotarget 2017; 8(68): 113153 doi: 10.18632/oncotarget.22615
|
| 33 |
Chi-Tan Hu, Jia-Ru Wu, Chuan-Chu Cheng, Wen-Sheng Wu. The Therapeutic Targeting of HGF/c-Met Signaling in Hepatocellular Carcinoma: Alternative Approaches. Cancers 2017; 9(6): 58 doi: 10.3390/cancers9060058
|
| 34 |
Mary Linton B Peters, Rebecca A Miksad. Cabozantinib in the treatment of hepatocellular carcinoma. Future Oncology 2017; 13(22): 1915 doi: 10.2217/fon-2017-0169
|
| 35 |
Laura M. McDonell, Kristin D. Kernohan, Kym M. Boycott, Sarah L. Sawyer. Receptor tyrosine kinase mutations in developmental syndromes and cancer: two sides of the same coin. Human Molecular Genetics 2015; 24(R1): R60 doi: 10.1093/hmg/ddv254
|
| 36 |
Ioanna Aggeletopoulou, Maria Kalafateli, Christos Triantos. Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: Where Do We Stand?. International Journal of Molecular Sciences 2024; 25(5): 2631 doi: 10.3390/ijms25052631
|
| 37 |
Nasim Ebrahimi, Elmira Fardi, Hajarossadat Ghaderi, Sahar Palizdar, Roya Khorram, Reza Vafadar, Masoud Ghanaatian, Fatemeh Rezaei-Tazangi, Payam Baziyar, Amirhossein Ahmadi, Michael R. Hamblin, Amir Reza Aref. Receptor tyrosine kinase inhibitors in cancer. Cellular and Molecular Life Sciences 2023; 80(4) doi: 10.1007/s00018-023-04729-4
|
| 38 |
Jiachen Wang, Zhao Wang, Jiaxiang Yuan, Qun Wang, Xinsheng Shen. Upregulation of miR-137 Expression Suppresses Tumor Growth and Progression via Interacting with DNMT3a Through Inhibiting the PTEN/Akt Signaling in HCC. OncoTargets and Therapy 2021; : 165 doi: 10.2147/OTT.S268570
|
| 39 |
Giuseppe Tridente. Adverse Events and Oncotargeted Kinase Inhibitors. 2017; : 457 doi: 10.1016/B978-0-12-809400-6.00021-4
|
| 40 |
Haiwei Zhang, Juan Zhao, Wei Yang, Zheng Li, Li Gong, Yongsheng Li. Hepatobiliary Cancers: An Interdisciplinary Approach. Interdisciplinary Cancer Research 2022; 3: 41 doi: 10.1007/16833_2022_96
|
| 41 |
Nicole F. Bonan, David Kowalski, Kaitie Kudlac, Kira Flaherty, J. Curtis Gwilliam, Lauren G. Falkenberg, Erik Maradiaga, Kathleen L. DeCicco-Skinner. Inhibition of HGF/MET signaling decreases overall tumor burden and blocks malignant conversion in Tpl2-related skin cancer. Oncogenesis 2019; 8(1) doi: 10.1038/s41389-018-0109-8
|
| 42 |
Mohamed Y. Zaky, Xiuxiu Liu, Taishu Wang, Shanshan Wang, Fang Liu, Duchuang Wang, Yueguang Wu, Yang Zhang, Dong Guo, Qianhui Sun, Qiong Li, Jinrui Zhang, Yingqiu Zhang, Weijie Dong, Zhenhua Liu, Shuyan Liu, Han Liu. Dynasore potentiates c-Met inhibitors against hepatocellular carcinoma through destabilizing c-Met. Archives of Biochemistry and Biophysics 2020; 680: 108239 doi: 10.1016/j.abb.2019.108239
|
| 43 |
Wei Jiang, Tao Li, Jiaojiao Guo, Jingjing Wang, Lizhou Jia, Xiao shi, Tingting Yang, Ruonan Jiao, Xin Wei, Zhenqing Feng, Qi Tang, Guozhong Ji. Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology 2021; 11 doi: 10.3389/fonc.2021.546586
|
| 44 |
Jung Han Kim, Hyeong Su Kim, Bum Jun Kim, Hyun Joo Jang, Jin Lee. Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review. Oncotarget 2017; 8(52): 90351 doi: 10.18632/oncotarget.20087
|
| 45 |
Mohamed Bouattour, Eric Raymond, Shukui Qin, Ann‐Lii Cheng, Uz Stammberger, Giuseppe Locatelli, Sandrine Faivre. Recent developments of c‐Met as a therapeutic target in hepatocellular carcinoma. Hepatology 2018; 67(3): 1132 doi: 10.1002/hep.29496
|
| 46 |
Susana Llerena, Nuria García-Díaz, Soraya Curiel-Olmo, Antonio Agraz-Doblas, Agustín García-Blanco, Helena Pisonero, María Varela, Miguel Santibáñez, Carmen Almaraz, Laura Cereceda, Nerea Martínez, María Teresa Arias-Loste, Ángela Puente, Luis Martín-Ramos, Carlos Rodríguez de Lope, Federico Castillo-Suescun, Carmen Cagigas-Fernandez, Pablo Isidro, Carlos Lopez-López, Marcos Lopez-Hoyos, Javier Llorca, Jesús Agüero, Benedicto Crespo-Facorro, Ignacio Varela, Miguel Ángel Piris, Javier Crespo, José Pedro Vaqué. Applied diagnostics in liver cancer. Efficient combinations of sorafenib with targeted inhibitors blocking AKT/mTOR. Oncotarget 2018; 9(56): 30869 doi: 10.18632/oncotarget.25766
|
| 47 |
Ujjwala Karmacharya, Diwakar Guragain, Prakash Chaudhary, Jun-Goo Jee, Jung-Ae Kim, Byeong-Seon Jeong. Novel Pyridine Bioisostere of Cabozantinib as a Potent c-Met Kinase Inhibitor: Synthesis and Anti-Tumor Activity against Hepatocellular Carcinoma. International Journal of Molecular Sciences 2021; 22(18): 9685 doi: 10.3390/ijms22189685
|
| 48 |
Sylvie Hermouet, Edith Bigot-Corbel, Betty Gardie, Mirella Giovarelli. Pathogenesis of Myeloproliferative Neoplasms: Role and Mechanisms of Chronic Inflammation. Mediators of Inflammation 2015; 2015(1) doi: 10.1155/2015/145293
|
| 49 |
Anna Qin, Yuan Qin, Joseph Lee, Anna Musket, Mingyao Ying, Giedre Krenciute, Francesco M. Marincola, Zhi Q. Yao, Phillip R. Musich, Qian Xie. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells. Journal of Translational Medicine 2023; 21(1) doi: 10.1186/s12967-023-04521-9
|
| 50 |
Jung-Hwan Yu, Joon Mee Kim, Ja Kyung Kim, Suk Jin Choi, Kwan Sik Lee, Jin-Woo Lee, Hye Young Chang, Jung Il Lee. Platelet-derived growth factor receptor α in hepatocellular carcinoma is a prognostic marker independent of underlying liver cirrhosis. Oncotarget 2017; 8(24): 39534 doi: 10.18632/oncotarget.17134
|